Stifel lowered the firm’s price target on Affimed to $1 from $2 and keeps a Hold rating on the shares following the company’s Q4 update. Management reiterated plans for the AFM13+AB-101 IND submission in the first half and to start a trial in 2023, but questions remain around the trial’s approval, lead-in phase, and duration, said the firm, which adds that it doesn’t think the AFM24 phase 1 data planned for Q2 or Q3 will "emerge as a new stock driver."
Protect Your Portfolio Against Market Uncertainty
- Discover companies with rock-solid fundamentals in TipRanks' Smart Value Newsletter.
- Receive undervalued stocks, resilient to market uncertainty, delivered straight to your inbox.
Published first on TheFly
See Insiders’ Hot Stocks on TipRanks >>
Read More on AFMD:
- Affimed Reports 2022 Financial Results and Operational Progress
- Affimed to Report Full Year 2022 Financial Results & Corporate Update on March 23, 2023
- Affimed Announces Presentations of Clinical Data from AFM13 Phase 2 REDIRECT and Pre-clinical Data Demonstrating CD16A Shedding Facilitates Repetitive Targeting of Tumor Cells by AFM13-armed NK Cells at the Annual Meeting of the American Association for Cancer Research
- AbCheck Announces Successful Completion of Research and Development Under Grant to Develop a Novel Microfluidics Technology for Functional Antibody Discovery
- Affimed to Participate in Fireside Chat at the H.C. Wainwright Cell Therapy Virtual Conference